Keywords: Daiichi Sankyo, Kixiana, First approval, Japan, Anticoagulant, VTE, Thromboembolism, Market
Daiichi Sankyo gains first approval for VTE drug Lixiana, in Japan
Article | 26 April 2011
Japanese drug major Daiichi Sankyo (TYO: 4568) has received its first marketing approval for Lixiana (edoxaban tosilate Hydrate, INN: edoxaban) from ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
